Prevention of Influenza: Recommendations for Influenza Immunization of Children, 2007–2008

The American Academy of Pediatrics recommends annual influenza immunization for all children with high-risk conditions who are 6 months of age and older, for all healthy children ages 6 through 59 months, for all household contacts and out-of-home caregivers of children with high-risk conditions and of healthy children younger than 5 years, and for all health care professionals. To more fully protect against the morbidity and mortality of influenza, increased efforts are needed to identify and immunize all children at high risk and all healthy children ages 6 through 59 months and to inform their parents when annual immunizations are due. Previously unimmunized children who are at least 6 months of age but younger than 9 years should receive 2 doses of influenza vaccine, given 1 month apart, beginning as soon as possible on the basis of local availability during the influenza season. If children in this cohort received only 1 dose for the first time in the previous season, it is recommended that 2 doses be administered in the current season. This recommendation applies only to the influenza season that follows the first year that a child younger than 9 years receives influenza vaccine. A child who then also fails to receive 2 doses the next year should be given only 1 dose per year from that point on. Influenza vaccine should also continue to be offered throughout the influenza season, even after influenza activity has been documented in a community. On the basis of global surveillance of circulating virus strains, the influenza vaccine may change from year to year; indeed, 1 of the 3 strains in the 2007–2008 vaccine is different from the previous year's vaccine. All health care professionals, influenza campaign organizers, and public health agencies should develop plans for expanding outreach and infrastructure to immunize all children for whom influenza vaccine is recommended. Appropriate prioritization of administering influenza vaccine will also be necessary when vaccine supplies are delayed or limited. Because the influenza season often extends into March, immunization against influenza is recommended to continue through late winter and early spring. Lastly, it is recommended that for the 2007–2008 season, and likely beyond, health care professionals do not prescribe amantadine or rimantadine for influenza treatment or chemoprophylaxis, because widespread resistance to these antiviral medications now exists among influenza A viral strains. However, oseltamivir and zanamivir can be prescribed for treatment or chemoprophylaxis, because influenza A and B strains remain susceptible.

[1]  R. Keren,et al.  Incidence, Complications, and Risk Factors for Prolonged Stay in Children Hospitalized With Community-Acquired Influenza , 2007, Pediatrics.

[2]  R. Baltimore,et al.  Prevention of Influenza: Recommendations for Influenza Immunization of Children, 2006–2007 , 2007, Pediatrics.

[3]  R. Baltimore,et al.  Antiviral Therapy and Prophylaxis for Influenza in Children , 2007, Pediatrics.

[4]  H. Lawson,et al.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[5]  C. Bridges,et al.  Vaccine Effectiveness Against Medically Attended, Laboratory-Confirmed Influenza Among Children Aged 6 to 59 Months, 2003–2004 , 2007, Pediatrics.

[6]  R. Walker,et al.  Live attenuated versus inactivated influenza vaccine in infants and young children. , 2007, The New England journal of medicine.

[7]  T. Stukel,et al.  Appropriate measures of influenza immunization program effectiveness , 2006, Vaccine.

[8]  Influenza vaccination coverage among children aged 6-23 months--United States, 2005-06 influenza season. , 2007, MMWR. Morbidity and mortality weekly report.

[9]  Update: Influenza activity--United States and worldwide, 2006-07 season, and composition of the 2007-08 influenza vaccine. , 2007, MMWR. Morbidity and mortality weekly report.

[10]  Influenza vaccination coverage among children aged 6-59 months--six immunization information system sentinel sites, United States, 2006-07 influenza season. , 2007, MMWR. Morbidity and mortality weekly report.

[11]  L. Brammer,et al.  Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007. , 2007, MMWR. Morbidity and mortality weekly report.

[12]  C. Byington,et al.  Epidemiology, Complications, and Cost of Hospitalization in Children With Laboratory-Confirmed Influenza Infection , 2006, Pediatrics.

[13]  Mandy A. Allison,et al.  Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. , 2006, The Journal of pediatrics.

[14]  R. Keren,et al.  Direct Medical Cost of Influenza-Related Hospitalizations in Children , 2006, Pediatrics.

[15]  C. Bridges,et al.  Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. , 2006, The Journal of infectious diseases.

[16]  T. Lieu,et al.  Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children , 2006, Emerging infectious diseases.

[17]  W. Gruber,et al.  Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections , 2006, The Pediatric infectious disease journal.

[18]  A. Monto,et al.  Immunization With Trivalent Inactivated Influenza Vaccine in Partially Immunized Toddlers , 2006, Pediatrics.

[19]  C. Bridges,et al.  The underrecognized burden of influenza in young children. , 2006, The New England journal of medicine.

[20]  Florence T. Bourgeois,et al.  Influenza and Other Respiratory Virus–Related Emergency Department Visits Among Young Children , 2006, Pediatrics.

[21]  L. Solberg,et al.  Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. , 2006, American journal of preventive medicine.

[22]  D. Thomson,et al.  Incidence of influenza in Ontario following the Universal Influenza Immunization Campaign. , 2006, Vaccine.

[23]  T. Heikkinen,et al.  Cost-effectiveness of influenza vaccination of healthy children. , 2006, Vaccine.

[24]  W. Schaffner,et al.  Multistate Surveillance for Laboratory-Confirmed, Influenza-Associated Hospitalizations in Children: 2003–2004 , 2006, The Pediatric infectious disease journal.

[25]  I. Maral,et al.  Effectiveness of Inactivated Influenza Vaccine for Prevention of Otitis Media in Children , 2006, The Pediatric infectious disease journal.

[26]  C. Glaser,et al.  Severe Pediatric Influenza in California, 2003–2005: Implications for Immunization Recommendations , 2006, Pediatrics.

[27]  A. Monto,et al.  Influenza Vaccine Immunogenicity in 6- to 23-Month-Old Children: Are Identical Antigens Necessary for Priming? , 2005, Pediatrics.

[28]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[29]  Keiji Fukuda,et al.  Influenza-associated deaths among children in the United States, 2003-2004. , 2005, The New England journal of medicine.

[30]  R. Yogev Influenza Vaccine Confusion: A Call for an Alternative Evidence-Based Approach , 2005, Pediatrics.

[31]  Ken P Kleinman,et al.  Identifying pediatric age groups for influenza vaccination using a real-time regional surveillance system. , 2005, American journal of epidemiology.

[32]  Pedro A Piedra,et al.  Live Attenuated Influenza Vaccine, Trivalent, Is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label Trial , 2005, Pediatrics.

[33]  M. Kolczak,et al.  Effectiveness of the 2003–2004 Influenza Vaccine Among Children 6 Months to 8 Years of Age, With 1 vs 2 Doses , 2005, Pediatrics.

[34]  J. Raphaël,et al.  [Guillain-Barré syndrome]. , 2005, La Revue du praticien.

[35]  Giovanni Apolone,et al.  Influenza vaccine in healthy children: a meta-analysis. , 2005, Vaccine.

[36]  A. Monto,et al.  A Comparison of 2 Influenza Vaccine Schedules in 6- to 23-Month-Old Children , 2005, Pediatrics.

[37]  T. Lieu,et al.  Values for preventing influenza-related morbidity and vaccine adverse events in children , 2005, Health and quality of life outcomes.

[38]  V Demicheli,et al.  Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review , 2005, The Lancet.

[39]  M. Meltzer,et al.  An economic analysis of annual influenza vaccination of children. , 2005, Vaccine.

[40]  Keiji Fukuda,et al.  Influenza-associated hospitalizations in the United States. , 2004, JAMA.

[41]  Benjamin Schwartz,et al.  Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. , 2004, Pediatrics.

[42]  T. Lieu,et al.  Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. , 2004, Pediatrics.

[43]  D. Krysan Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. , 2004, The Journal of pediatrics.

[44]  J. Bartlett,et al.  Daptomycin, a new cyclic lipopeptide antibiotic, for the treatment of resistant gram-positive organisms , 2004 .

[45]  N. Sugaya [Influenza virus infection in children]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[46]  O. Ruuskanen,et al.  Influenza A and B virus infections in children. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[48]  M. Rennels,et al.  Reduction of the influenza burden in children. , 2002, Pediatrics.

[49]  M. Tashiro,et al.  Encephalitis and encephalopathy associated with an influenza epidemic in Japan. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  G. Boivin,et al.  Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  K. Edwards,et al.  Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. , 2002, The Journal of infectious diseases.

[52]  M. Peiris,et al.  Influenza A infection is an important cause of febrile seizures. , 2001, Pediatrics.

[53]  W. Dupont,et al.  Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience , 2001, The Pediatric infectious disease journal.

[54]  Lihan K. Yan,et al.  Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. , 2001, Pediatrics.

[55]  K. Nichol,et al.  Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. , 2001, Archives of internal medicine.

[56]  H. Dibarboure,et al.  Safety and immunogenicity of a paediatric presentation of an influenza vaccine , 2000, Archives of disease in childhood.

[57]  K. Neuzil,et al.  The burden of influenza illness in children with asthma and other chronic medical conditions. , 2000, The Journal of pediatrics.

[58]  M. Nettleman,et al.  Economic Impact of Influenza Vaccination in Preschool Children , 2000, Pediatrics.

[59]  K. O'Brien,et al.  Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  Lihan K. Yan,et al.  Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. , 2000, The Journal of pediatrics.

[61]  E F Mitchel,et al.  The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. , 2000, The New England journal of medicine.

[62]  R. Davis,et al.  Influenza and the rates of hospitalization for respiratory disease among infants and young children. , 2000, The New England journal of medicine.

[63]  M. Meltzer,et al.  The economic impact of pandemic influenza in the United States: priorities for intervention. , 1999, Emerging infectious diseases.

[64]  J. A. McCullers,et al.  Influenza B virus encephalitis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  K. Neuzil,et al.  Influenza-associated morbidity and mortality in young and middle-aged women. , 1999, JAMA.

[66]  T. Heikkinen,et al.  Prevalence of various respiratory viruses in the middle ear during acute otitis media. , 1999, The New England journal of medicine.

[67]  L. Simonsen,et al.  Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. , 1998, American journal of epidemiology.

[68]  N. Cox,et al.  Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  A. Kaplan,et al.  Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. , 1998, Vaccine.

[70]  R. Kerstens,et al.  IMMUNOGENICITY AND TOLERABILITY OF A TRIVALENT INFLUENZA SUBUNIT VACCINE (INFLUVAC®) IN HIGH‐RISK CHILDREN AGED 6 MONTHS TO 4 YEARS , 1997, The British journal of clinical practice.

[71]  J L Nielsen,et al.  [Influenza vaccination]. , 1997, Ugeskrift for laeger.

[72]  A. Frank,et al.  Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. , 1996, Pediatrics.

[73]  E. Walter,et al.  Influenza a vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care , 1996 .

[74]  N. Cox,et al.  Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. , 1995, The Journal of infectious diseases.

[75]  N. Sugaya,et al.  Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. , 1994, JAMA.

[76]  K. Edwards,et al.  Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. , 1994, The Pediatric infectious disease journal.

[77]  M. Levin,et al.  Safety and immunogenicity of a purified haemagglutinin antigen in very young high-risk children. , 1994, Vaccine.

[78]  J. Patel,et al.  Effect of viral respiratory tract infection on outcome of acute otitis media. , 1992, The Journal of pediatrics.

[79]  T. Heikkinen,et al.  Influenza vaccination in the prevention of acute otitis media in children. , 1991, American journal of diseases of children.

[80]  R. Couch,et al.  Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. , 1991, The Journal of infectious diseases.

[81]  R. Couch,et al.  Live attenuated and inactivated influenza vaccine in school-age children. , 1990, American journal of diseases of children.

[82]  Henry Nider,et al.  Report of the Committee on Infectious Diseases , 1989 .

[83]  O. Ruuskanen,et al.  Acute otitis media and respiratory virus infections. , 1989, The Pediatric infectious disease journal.

[84]  A R Hinman,et al.  Assessing vaccine efficacy in the field. Further observations. , 1988, Epidemiologic reviews.

[85]  W. P. Glezen,et al.  Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. , 1987, The American review of respiratory disease.

[86]  M. Decker,et al.  Acute respiratory disease associated with influenza epidemics in Houston, 1981-1983. , 1987, The Journal of infectious diseases.

[87]  E. D. Kilbourne,et al.  Influenza in Man , 1987 .

[88]  B. Murphy,et al.  Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus , 1986, Journal of clinical microbiology.

[89]  W. Barker,et al.  Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. , 1986, American journal of public health.

[90]  C. Hall,et al.  Influenza A virus infection imitating bacterial sepsis in early infancy , 1984, Pediatric infectious disease.

[91]  W. P. Glezen,et al.  Trivalent, inactivated influenza virus vaccine in children with sickle cell disease. , 1983, American journal of diseases of children.

[92]  A. Monto,et al.  Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children--a multicentered evaluation of dosage and safety. , 1983, Reviews of infectious diseases.

[93]  J. L. Montagne,et al.  Summary of clinical trials of inactivated influenza vaccine - 1978. , 1983, Reviews of infectious diseases.

[94]  J. C. Bell,et al.  Influenza vaccination. , 1983, JAMA.

[95]  R B Couch,et al.  Immunity to influenza in man. , 1983, Annual review of microbiology.

[96]  J. Mullooly,et al.  Impact of type A influenza on children: a retrospective study. , 1982, American journal of public health.

[97]  R. Chanock,et al.  Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines , 1982, Infection and immunity.

[98]  Glezen Wp,et al.  SERIOUS MORBIDITY AND MORTALITY ASSOCIATED WITH INFLUENZA EPIDEMICS , 1982 .

[99]  W. P. Glezen,et al.  Serious morbidity and mortality associated with influenza epidemics. , 1982, Epidemiologic reviews.

[100]  P. Steinherz,et al.  Immunization against influenza in children with cancer: results of a three-dose trial. , 1982, The Journal of infectious diseases.

[101]  J. Mullooly,et al.  Impact of epidemic type A influenza in a defined adult population. , 1980, American journal of epidemiology.

[102]  J A Bryan,et al.  Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. , 1979, American journal of epidemiology.

[103]  J. Oxford,et al.  The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection , 1979, Journal of Hygiene.

[104]  R. Couch,et al.  Interpandemic influenza in the Houston area, 1974-76. , 1978, The New England journal of medicine.

[105]  W. Vaughn,et al.  Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. , 1977, The Journal of infectious diseases.

[106]  D. Tyrrell,et al.  The Influenza Viruses and Influenza , 1976 .

[107]  A. Monto,et al.  The Tecumseh Study of Respiratory Illness. IX. Occurence of influenza in the community, 1966--1971. , 1975, American journal of epidemiology.

[108]  A. Monto,et al.  The Tecumseh study of respiratory illness. VII. Further observations on the occurrence of respiratory syncytial virus and Mycoplasma pneumoniae infections. , 1971, American journal of epidemiology.